ULTI Ultimovacs

Ultimovacs ASA – Mandatory notification of trade 

Ultimovacs ASA – Mandatory notification of trade 



Reference is made to the stock exchange announcement by Ultimovacs ASA (the "Company") on 17 December 2024 regarding the agreement to combine its business with Zelluna Immunotherapy AS (the "Business Combination") and the fully committed private placement (the "Private Placement" and together with the Business Combination, the "Transactions"). 



Please see the attached forms for information on the conditional allocation of shares in the Company to closely related parties of primary insiders in connection with the Transactions. The transactions reported by in the forms are conditional upon approval by an extraordinary general meeting of the Company and the subsequent completion of the Business Combination and the Private Placement. 



This information is subject to the disclosure requirements in article 19 of Regulation EU 596/2014 (the "EU Market Abuse Regulation") and section 5-12 of the Norwegian Securities Trading Act.

 

Attachment



EN
17/12/2024

Underlying

ULTIUltimovacs

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Ultimovacs

ABGSC Healthcare Research ... (+2)
  • ABGSC Healthcare Research
  • Alexander Krämer
8h / 21m 8h / 21m 1 EN
 PRESS RELEASE
Free
ULTI ULTIMOVACS

ULTI – EX. RIGHT TO PARTICIPATE IN POTENTIAL REPAIR OFFERING TODAY

ULTI – EX. RIGHT TO PARTICIPATE IN POTENTIAL REPAIR OFFERING TODAY Issuer name: Ultimovacs ASA Ex. date: 18 December 2024 Type of corporate action: Potential repair offering  Other information: Any repair offering is subject to the prior publication of a prospectus in accordance with applicable legislation. This information is published in accordance with the requirements of the Continuing Obligations. 

8h / 59m 1 EN
 PRESS RELEASE
Free
ULTI ULTIMOVACS

Key information relating to the potential subsequent repair offering t...

Key information relating to the potential subsequent repair offering to be carried out by Ultimovacs ASA Reference is made to the stock exchange announcement by Ultimovacs ASA ("Ultimovacs" or the "Company") on 17 December 2024 regarding the agreement to combine its business with Zelluna Immunotherapy AS ("Zelluna"), the fully committed private placement (the "Private Placement"), and the intention to carry out a subsequent repair offering (the "Subsequent Offering") of up to 3,846,153 new shares at a subscription price per new share of NOK 2.60, directed towards shareholders of Ultimovacs ...

21h / 20m 1 EN
 PRESS RELEASE
Free
ULTI ULTIMOVACS

Ultimovacs ASA – Mandatory notification of trade 

Ultimovacs ASA – Mandatory notification of trade  Reference is made to the stock exchange announcement by Ultimovacs ASA (the "Company") on 17 December 2024 regarding the agreement to combine its business with Zelluna Immunotherapy AS (the "Business Combination") and the fully committed private placement (the "Private Placement" and together with the Business Combination, the "Transactions").  Please see the attached forms for information on the conditional allocation of shares in the Company to closely related parties of primary insiders in connection with the Transactions. The transactio...

21h / 34m 1 EN
 PRESS RELEASE
Free
ULTI ULTIMOVACS

ULTIMOVACS ANNOUNCES AGREEMENT TO COMBINE ITS BUSINESS WITH ZELLUNA IM...

ULTIMOVACS ANNOUNCES AGREEMENT TO COMBINE ITS BUSINESS WITH ZELLUNA IMMUNOTHERAPY AND INTENTION TO LAUNCH FULLY COMMITTED PRIVATE PLACEMENT NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN OR ANY JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. Ultimovacs ASA (OSE: ULTI) ("Ultimovacs" or the "Company") and Zelluna Immunotherapy AS ("Zelluna"), a privately held company pioneering the development of “off the shelf” T- Cell Receptor Natural Killer (TCR-NK) cell therapies for the...

23h / 6m 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch